HAIRY CELL LEUKEMIA

This study tests a combination of two drugs, tovorafenib and rituximab, in people with classical hairy cell leukemia that has returned or not responded to treatment. It also compares this new combo to the current standard treatment (cladribine plus rituximab) for newly diagnosed …

This study compares a new drug combination (vemurafenib plus obinutuzumab) to the standard treatment (cladribine plus rituximab) for people with untreated hairy cell leukemia. The goal is to see which approach causes fewer side effects and works better at eliminating cancer cells…

This study tests a new treatment for hairy cell leukemia (HCL) using a patient's own immune cells, called T cells, that are modified in a lab to recognize and attack cancer cells. The treatment is for adults with HCL who have not responded to or cannot have standard therapies. Th…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This study tests whether taking two pills together (encorafenib and binimetinib) works better than the current drug vemurafenib for people with hairy cell leukemia that did not respond to treatment or came back. About 45 adults with a specific gene change (BRAF V600) will take th…

This study tests a drug called binimetinib for people with hairy cell leukemia that does not have the BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer. About 40 adults w…

This study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive cladribine chemotherapy to kill cancer cells, then rituximab immunotherapy to help the immune system attack any remaining cells. The goal is to achieve complete remission a…